Picture of HUTCHMED (China) logo

HCM HUTCHMED (China) News Story

gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

REG - Hutchmed China Ltd - 2021 Annual Report and Notice of AGM

For best results when printing this announcement, please click on link below:

RNS Number : 6499F  Hutchmed (China) Limited  23 March 2022


2021 Annual Report and Notice of Annual General Meeting


Hong Kong, Shanghai, & Florham Park, NJ - Wednesday, March 23, 2022:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report
together with the Notice of Annual General Meeting and the Form of Proxy ("AGM
Materials") will be posted to shareholders on March 24, 2022 who have elected
to receive the AGM Materials in printed form. The documents can also be
accessed from the HUTCHMED website (www.hutch-med.com
(https://www.hutch-med.com/) ).


The 2022 Annual General Meeting ("AGM") will be held at the Conference Room,
18(th) Floor, Hutchison Telecom Tower, 99 Cheung Fai Road, Tsing Yi, Hong Kong
on Wednesday, April 27, 2022 at 6:00 pm Hong Kong Time (11:00 am London Time).


To safeguard the health and safety of shareholders, HUTCHMED encourages
shareholders to: (i) attend the AGM online and vote by means of electronic
facilities; or (ii) exercise their right to vote at the AGM by appointing the
Chairman of the AGM as their proxy. Shareholders will be able to view a live
webcast of the AGM through the website of the Company at
www.hutch-med.com/event/ (https://www.hutch-med.com/event/) . All registered
shareholders will also receive a letter containing log in details and
information on how to access the webcast.



HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 4,600
personnel across all its companies, at the center of which is a team of about
1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch-med.com (https://www.hutch-med.com/)
or follow us on LinkedIn (https://www.linkedin.com/company/hutchmed/) .


 Investor Enquiries
 Mark Lee, Senior Vice President    +852 2121 8200
 Annie Cheng, Vice President        +1 (973) 567 3786
 Media Enquiries
 Americas - Brad Miles,             +1 (917) 570 7340 (Mobile)

Solebury Trout
 Europe - Ben Atwell / Alex Shaw,   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                    +44 7779 545 055 (Mobile)

 Asia - Zhou Yi,                    +852 9783 6894 (Mobile)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,  +44 (20) 7886 2500

Panmure Gordon (UK) Limited


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)

Recent news on HUTCHMED (China)

See all news